Menu Back toOptimizing Cell and Gene Therapy Clinical Trial Virtualization and Remote Monitoring in the Time of COVID-19

DIA 2021 Global Annual Meeting


Optimizing Cell and Gene Therapy Clinical Trial Virtualization and Remote Monitoring in the Time of COVID-19

Session Chair(s)

Monica Ravindra Shah, DrMed, FACC

Monica Ravindra Shah, DrMed, FACC

  • Therapeutic Science and Strategy Unit Vice President and Head, CAGT COE
  • IQVIA, United States
Using virtual-hybrid and remote solutions, we describe an innovative model for monitoring and executing cell and gene therapy clinical trials during COVID-19. These approaches serve as an instructive path forward for the future of these therapies.
Learning Objective : Describe evolving strategies with innovative solutions for delivering cell and gene therapy trials during COVID-19; Discuss specific areas of trial risk, patient safety, data quality, and how virtual and remote activities are being successfully deployed; Analyze metrics to date and how these support a paradigm shift in the operation of these trials.

Speaker(s)

Chris Ashby Learn, PhD, PMP

Industry Update

Chris Ashby Learn, PhD, PMP

  • Senior Director, Clinical Development
  • Istari Oncology, United States
Erin  Finot, MBA, MS

Industry Update

Erin Finot, MBA, MS

  • Vice President, Immuno-Oncology
  • IQVIA, United States
Molly  Mjolsness, MBA

Industry Update

Molly Mjolsness, MBA

  • Senior Client Delivery Manager
  • Be The Match Biotherapies, United States